Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).
Brian Matthew Wolpin, Eileen Mary O'Reilly, Y. Ko et al. · Journal of Clinical Oncology · 2011
4031 Background: A is a fully human monoclonal antibody directed against prostate stem cell antigen (PSCA), a cell surface protein expressed on pancreatic cancer cells. Methods: Previously untreated pts with pathologically- confirmed mPC and ECOG performance status (PS) of 0-1 were randomized 1:2 to G (1000 mg/m2 IV over 30 minutes weekly x7, 1 week rest, then weekly x3 q4weeks) or G plus A (48 mg/kg loading dose, then 24 mg/kg q3weeks over 60 minutes IV), stratified by region (North America vs. Europe/Russia). Primary endpoint was 6-month (mo) overall survival (OS) in the intention-to-treat population. With a planned sample size of 185 pts, the study was designed to detect an improvement in 6-mo OS from 45% to 65% with 90% power and one-sided α=0.10. Tumor samples were collected for pre-planned secondary analyses by PSCA expression. Results: 196 pts (63 in G arm, 133 in G+A arm) were enrolled from 04/09-05/10 at 55 centers in U.S., Canada, Spain, France, and Russia. For G/G+A arms: median age 63/62 years, male 40/56%, PS 1 83/73%, deaths to date 73/67%. Grade 3/4 adverse events (G/G+A; %): any 63/78%, neutropenia 14/26%, thrombocytopenia 2/9%, and pulmonary embolism 2/6%. Tumor tissue was available from 118 pts (60%) for immunohistochemistry (IHC): 64 pts strong/moderate (pos) and 54 weak/no staining (neg) for PSCA. Efficacy data for 6-mo OS are shown in the table. Disease control rates (PR+SD) and 95% CI were 49% (36, 62) for G arm and 50% (41, 58) for G+A arm in the full population, and 57% (34, 78) for G arm and 70% (54, 83) for G+A arm in the PSCA pos population. Conclusions: The addition of A to G is well-tolerated and resulted in a trend toward improved 6-mo OS, primarily in patients with moderate or strong tumor PSCA expression. Follow-up is ongoing for secondary endpoints. Population 6-mo OS (%) (95% CI) Difference (95% CI) P value* G G+A (G+A) - A Full 44 (32, 58) 56 (47, 64) 11 (-4, 26) 0.07 PSCA pos 57 (34, 78) 74 (59, 87) 17 (-10, 42) 0.08 PSCA neg 32 (13, 57) 34 (19, 52) 3 (-25, 30) 0.42 PSCA not available 44 (23, 66) 55 (41, 68) 11 (-13, 35) 0.19 *One-sided Cochran-Mantel-Haenszel test.
Cited by 8 works. doi:10.1200/jco.2011.29.15_suppl.4031